$KRSA News

Wedbush Initiates Coverage On Korsana Biosciences with Outperform Rating, Announces Price Target of $44

Korsana Biosciences (KRSA) At $31.20 Leaves Valuation Questions On A Sharp 2026 Run

Guggenheim Initiates Coverage On Korsana Biosciences with Buy Rating, Announces Price Target of $70

Stifel Initiates Coverage On Korsana Biosciences with Buy Rating, Announces Price Target of $43

TD Cowen Initiates Coverage On Korsana Biosciences with Buy Rating

UBS Initiates Coverage On Korsana Biosciences with Buy Rating, Announces Price Target of $55

Korsana Biosciences Completes Closing of Merger with Cyclerion Therapeutics and Previously Announced Private Placement of $380 Million

Cyclerion Therapeutics Announces September 4 Record Date For Contingent Value Rights Distribution To Common And Series A Preferred Holders In Connection With Planned Korsana Biosciences Merger

Cyclerion Therapeutics Q1 EPS $(0.76) Down From $(0.56) YoY

Cyclerion Therapeutics (CYCN) Merges With Korsana Biosciences to Advance Alzheimer’s Pipeline

Penny Stock CYCN Surged More Than 300% Yesterday. Why, And Should You Chase the Rally Here?

Cyclerion Therapeutics Stock Soars 350% On Korsana Merger, $380 Million Financing

Cyclerion Therapeutics, Inc. (CYCN) M&A Call Prepared Remarks Transcript

Cyclerion Therapeutics shares are trading higher after the company announced it entered into a definitive merger agreement with Korsana Biosciences.

Cyclerion Therapeutics shares are trading higher after the company announced it entered into a definitive merger agreement with Korsana Biosciences.

Cyclerion And Korsana Biosciences Announce All-Stock Merger With $380M Private Financing To Advance Alzheimer's Drug KRSA-028 Through 2029

CYCN: Positive Feedback from FDA Sets Stage for Phase 2 Trial of CYC-126 in 2H26

Cyclerion Therapeutics Announces Progress Toward CYC-126 Phase 2 Proof-of-Concept Study with FDA Feedback and Formation of Clinical Advisory Board

Watching Cyclerion Therapeutics; Zacks Small-Cap Research Gives Stock $8.00 Price Valuation

CYCN: Engineering a Reset; Initiating Coverage of Cyclerion Therapeutics…